Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Aerosolized drugs: current regulatory perspective.

¹Regulatory Affairs, North America LLC, Durham, North Carolina 27722, USA. nchew@ranallc.com

Respiratory Care

|July 14, 2000

Summary

Understanding how the Center for Drug Evaluation and Research (CDER) interprets safety and effectiveness can improve aerosol drug development. Early consideration of regulatory requirements aids efficient decision-making and faster evaluation of drug candidates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Methanol outbreak: a Malaysian tertiary hospital experience.

International journal of emergency medicine·2020

Same author

STAT-3 regulation of CXCR4 is necessary for the prenylflavonoid Icaritin to enhance mesenchymal stem cell proliferation, migration and osteogenic differentiation.

Biochimica et biophysica acta. General subjects·2018

Same author

The prenylflavonoid Icaritin enhances osteoblast proliferation and function by signal transducer and activator of transcription factor 3 (STAT-3) regulation of C-X-C chemokine receptor type 4 (CXCR4) expression.

Bone·2017

Same author

Extra-corporeal membrane oxygenation in the management of 2009 influenza A (H1N1) refractory respiratory failure.

Irish medical journal·2011

Same author

Consensus statement: aerosols and delivery devices.

Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine·2009

Same author

Case report: Unusual orbital invasion by a giant prolactinoma.

The British journal of radiology·2008

Area of Science:

Pharmaceutical Sciences
Regulatory Science
Drug Development

Background:

Regulatory agencies like the Center for Drug Evaluation and Research (CDER) interpret safety and effectiveness criteria for drug approval.
The Division of Pulmonary Drug Products within CDER has specific considerations for aerosolized medications.
Early-stage drug development benefits from a clear understanding of regulatory expectations.

Purpose of the Study:

To elucidate how CDER, particularly the Division of Pulmonary Drug Products, interprets regulatory concepts of safety and effectiveness.
To demonstrate how incorporating regulatory insights early in product development can enhance data value.
To highlight the importance of regulatory considerations for efficient decision-making in aerosol drug development.

Main Methods:

Analysis of regulatory guidance documents and precedents related to pulmonary drug products.
Review of CDER's interpretation of safety and effectiveness data for aerosolized drugs.
Case study or conceptual framework illustrating the impact of early regulatory engagement.

Main Results:

Understanding CDER's interpretation of safety and effectiveness adds value to developed data.
Proactive consideration of regulatory requirements facilitates rapid evaluation of aerosol drug candidates.
Informed regulatory awareness leads to more efficient decisions regarding further product development.

Conclusions:

Integrating knowledge of regulatory expectations into early development optimizes the evaluation of aerosol drug candidates.
Collaboration with regulatory bodies and stakeholders ensures alignment with safety and effectiveness standards.
Patient and practitioner input influences the evolution of new drug regulations.

Related Experiment Videos